Journal Scans
Bevacizumab Safety in Patients With Central Nervous System Metastases
Bevacizumab Safety in Patients With Central Nervous System Metastases
B Besse, SF Lasserre, P Compton, J Huang, S Augustus, U-P Rohr
20100001
2010 Jan 1
Clin Cancer Res
Bevacizumab Safety in Patients With Central Nervous System Metastases
Clin Cancer Res. 2010 Jan 1;16(1):269-278, B Besse, SF Lasserre, P Compton, J Huang, S Augustus, U-P Rohr
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Bevacizumab is a selective inhibitor of human vascular endothelial growth factor (VEGF) activity that has demonstrated efficacy in combination with chemotherapy in several types of cancer. Patients with central nervous system (CNS) metastases are excluded from clinical trials with bevacizumab because of a purported link with cerebral hemorrhage. During a clinical trial in 1997, a patient with an undiagnosed brain metastasis from hepatocellular carcinoma who was being treated with bevacizumab died...
